Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) is a leading biopharmaceutical company headquartered in San Francisco, California, with additional manufacturing operations in Huntsville, Alabama. The company specializes in developing novel therapeutics using its advanced polymer conjugate chemistry technology platform. Nektar has a robust, wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology, alongside a portfolio of approved partnered medicines.
Oncology: Nektar is actively working on activating the body's natural tumor-fighting mechanisms. Several immuno-oncology drug candidates are being studied in clinical trials for various cancer indications. One of the most notable candidates is NKTR-255, which targets the IL-15 pathway to enhance anti-tumor immune response by boosting the proliferation and persistence of NK and CD8+ T cells.
Immunology: The company is dedicated to addressing imbalances in the immune system to restore self-tolerance and achieve immune homeostasis. Rezpegaldesleukin (REZPEG), a novel T regulatory cell biologic, is being evaluated in Phase 2b studies for atopic dermatitis and alopecia areata. This biologic aims to dampen inflammatory responses and restore immune balance.
Virology: Nektar is exploring the use of selective immuno-modulators to combat viral infections by modulating the immune system's response. The company's technology has enabled the development of nine approved products for partners, including some of the top biopharmaceutical companies.
Recent Achievements: Recent highlights include the initiation of a Phase 2b study for REZPEG in severe to very severe alopecia areata, and a poster presentation at the 65th American Society of Hematology Annual Meeting showcasing preclinical data on NKTR-255. These studies underscore Nektar's commitment to advancing innovative treatments for critical health conditions.
Financial Condition: On March 4, 2024, Nektar announced a securities purchase agreement with TCGX for a $30 million private placement, bolstering its financial position and extending its cash runway into the third quarter of 2026. Additionally, the company reported ongoing clinical trials and collaborations, including studies with CAR-T cell therapies and PD-1 immunotherapies, further enhancing its pipeline.
For more information about Nektar Therapeutics and its pioneering drug development programs, visit Nektar's official website.
Nektar Therapeutics (NKTR) reported Q2 2024 financial results with revenue of $23.5 million, up from $20.5 million in Q2 2023. The company's cash position was $290.6 million as of June 30, 2024, expected to support operations into Q3 2026. Net loss for Q2 2024 was $52.4 million or $0.25 per share. Nektar is progressing with Phase 2 studies of rezpegaldesleukin in atopic dermatitis and alopecia areata, with topline data expected in H1 and mid-2025, respectively. The company is also advancing NKTR-0165, a TNFR2 agonist antibody, towards IND submission in mid-2025. Recent data on NKTR-255 in combination with CAR-T therapy showed promising results in B-cell acute lymphoblastic leukemia patients.
Nektar Therapeutics (Nasdaq: NKTR) has announced that it will release its financial results for the second quarter of 2024 on Thursday, August 8, 2024, after the close of U.S.-based financial markets. The company's President and CEO, Howard Robin, will host a conference call at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time to review the results.
Investors and interested parties can access the press release and live audio-only webcast of the conference call through a link on the Home Page and Investors section of Nektar's website. The web broadcast will be available for replay until September 8, 2024. To participate in the conference call, pre-registration is required through the Nektar Earnings Call Registration link.
Nektar Therapeutics (Nasdaq: NKTR) unveiled preclinical data on NKTR-0165, a TNFR2 agonist antibody aimed at treating inflammatory diseases, at the EULAR 2024 Congress. NKTR-0165 is designed to selectively stimulate TNFR2 receptor activity, which is important for inflammation control and is associated with various autoimmune diseases like ulcerative colitis and vitiligo. Preclinical studies revealed that NKTR-0165 enhances Treg cell function, a key component in immune response regulation, without affecting TNFR1 signaling. IND-enabling studies are ongoing, with human trials expected in the first half of 2025.
Nektar Therapeutics (Nasdaq: NKTR) management will present at two upcoming investor conferences: the Jefferies Healthcare Conference in New York City on June 6, 2024, at 3:30 p.m. ET, and the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on June 10, 2024, at 2:00 p.m. ET.
The presentations will be webcast live and accessible via the Investor Events section on the Nektar website. Recordings of the webcasts will be available until July 6, 2024, and July 10, 2024, respectively.
Nektar Therapeutics reported their financial results for the first quarter of 2024, showing revenue of $21.6 million and a net loss of $36.8 million. The company's cash and investments were $326.0 million as of March 31, 2024, supporting operations until the third quarter of 2026. Progress was noted in their immunology and inflammation pipeline, with expectations for topline data from ongoing trials in 2025. Nektar also entered into a private placement financing agreement generating $30 million in gross proceeds.
Nektar Therapeutics (NKTR) will announce its financial results for the first quarter of 2024 on May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and CEO, will host a conference call to review the results. The press release and webcast link will be available on the Nektar website. Conference call replay will be accessible until June 9, 2024.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
What does Nektar Therapeutics specialize in?
What are some of Nektar's recent achievements?
What is NKTR-255?
What is REZPEG?
Who are Nektar's partners?
Where is Nektar Therapeutics headquartered?
What is the financial outlook for Nektar?
What are the main focus areas for Nektar in oncology?
How does Nektar address immunology?
How can I find more information about Nektar Therapeutics?
